Amgen-AMGN possible impact from AMGN vs. Roche hearing@SBSH
Oral arguments of Rochs's request for a dismissal of AMGN's EPO patent infringement complaint are expected to begin on 5/10 at 2pm EST. The firm says its possible for the Judge to issue a decision at the hearing. If he rules in favor of Roche, the firm sees downside in AMGN shares limited to 1-2 points. If the Judge rules to proceed with the case or to pursue AMGN's request of discovery jurisdiction, the analyst believes shares could move up 5-10%. AMGN shares are Buy rated. For the latest breaking news, listen to Fly Radio
Know how to make God laugh?
Tell Her your plans ....